Hyphens Pharma International Limited (SGX:1J5)

Market Cap	100.38M +12.1%
Revenue (ttm)	177.37M -9.2%
Net Income	5.84M -42.7%
EPS	0.02 -42.6%
Shares Out	308.87M
PE Ratio	17.47
Forward PE	8.13
Dividend	0.02 (4.69%)
Ex-Dividend Date	May 6, 2026

Volume	50,100
Open	0.3250
Previous Close	0.3200
Day's Range	0.3250 - 0.3250
52-Week Range	0.2900 - 0.3950
Beta	0.22
Analysts	Strong Buy
Price Target	0.42 (+29.23%)
Earnings Date	Aug 10, 2026

About SGXC:1J5

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Pharmaceutical and Medical Aesthetics; Proprietary Brands; and Digital Platform and E-Pharmacy segments. The Pharmaceutical and Medical Aesthetics segment markets and sells a range of pharmaceutical and medical aesthetics products, including the Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Pia...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 474
• Stock Exchange: Singapore Exchange - Catalist
• Ticker Symbol: 1J5

Financial Performance

In 2025, SGXC:1J5's revenue was 177.37 million, a decrease of -9.24% compared to the previous year's 195.42 million. Earnings were 5.84 million, a decrease of -42.67%.

Analyst Summary

According to 2 analysts, the average rating for 1J5 stock is "Strong Buy." The 12-month stock price target is $0.42, which is an increase of 29.23% from the latest price.

Price Target

$0.42

(29.23% upside)

Analyst Consensus: Strong Buy